Infliximab for the treatment of refractory Adamantiades-Behçet disease with articular, intestinal, cerebral and ocular involvement.
Donghi
Davide
D
Mainetti
Carlo
C
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy* / Q000473:pathology; D001241:Aspirin / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000473:pathology; D002908:Chronic Disease; D003078:Colchicine / Q000627:therapeutic use; D015235:HLA-B Antigens / Q000032:analysis; D059949:HLA-B51 Antigen; D006801:Humans; D007079:Ileitis / Q000188:drug therapy* / Q000473:pathology; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D031300:Retinal Vasculitis / Q000188:drug therapy* / Q000473:pathology; D012611:Scrotum / Q000473:pathology; D020293:Vasculitis, Central Nervous System / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D015235:HLA-B Antigens; D059949:HLA-B51 Antigen; D000069285:Infliximab; D001379:Azathioprine; D001241:Aspirin; D003078:Colchicine; D011241:Prednisone